• Gaush Meditech posted revenue of RMB 595.1 million, down 8.9% year over year for the six months ended June 30, 2026.
• Net profit fell 57.9% to RMB 15.1 million; basic earnings per share slid to RMB 0.12.
• Distribution Products revenue dropped 19.4% to RMB 263.5 million, due to policy-driven demand shifts and a terminated femtosecond cataract agency deal.
• Proprietary Products revenue rose 4.6% to RMB 212.3 million, led by intraocular lens revenue of RMB 189.3 million, up 11%.
• Management expects several self-developed products to enter mass production and launch in the second half of 2026 to support growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gaush Meditech Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260828-12304887), on August 28, 2026, and is solely responsible for the information contained therein.